442 reports of this reaction
1.6% of all LEDIPASVIR AND SOFOSBUVIR reports
#8 most reported adverse reaction
VOMITING is the #8 most commonly reported adverse reaction for LEDIPASVIR AND SOFOSBUVIR, manufactured by Gilead Sciences, Inc. There are 442 FDA adverse event reports linking LEDIPASVIR AND SOFOSBUVIR to VOMITING. This represents approximately 1.6% of all 27,933 adverse event reports for this drug.
Patients taking LEDIPASVIR AND SOFOSBUVIR who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for LEDIPASVIR AND SOFOSBUVIR, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for LEDIPASVIR AND SOFOSBUVIR:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 442 FDA reports for LEDIPASVIR AND SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 1.6% of all adverse event reports for LEDIPASVIR AND SOFOSBUVIR, making it a notable side effect.
If you experience vomiting while taking LEDIPASVIR AND SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.